Pacira BioSciences' Operating Expenses fell 4379.94% to $173.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $675.2 million, marking a year-over-year decrease of 1113.73%. This contributed to the annual value of $774.3 million for FY2024, which is 3184.63% up from last year.
Pacira BioSciences' Operating Expenses amounted to $173.2 million in Q3 2025, which was down 4379.94% from $172.6 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Operating Expenses registered a high of $308.1 million during Q3 2024, and its lowest value of $96.3 million during Q3 2021.
Moreover, its 5-year median value for Operating Expenses was $149.8 million (2024), whereas its average is $154.4 million.
As far as peak fluctuations go, Pacira BioSciences' Operating Expenses surged by 11073.15% in 2024, and later plummeted by 4379.94% in 2025.
Pacira BioSciences' Operating Expenses (Quarter) stood at $155.0 million in 2021, then rose by 17.33% to $181.8 million in 2022, then decreased by 18.57% to $148.1 million in 2023, then rose by 9.77% to $162.5 million in 2024, then increased by 6.52% to $173.2 million in 2025.
Its Operating Expenses stands at $173.2 million for Q3 2025, versus $172.6 million for Q2 2025 and $166.9 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value